Mptp Induced Dopaminergic Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin that selectively destroys dopaminergic neurons in the substantia nigra, producing a precise model of Parkinson's disease in primates and mice.
This page provides comprehensive information about the subject's role in neurodegenerative diseases. The subject participates in various molecular pathways and cellular processes relevant to Alzheimer's disease, Parkinson's disease, and related conditions.
- Crosses blood-brain barrier
- Converted to MPP+ by MAO-B in astrocytes
- Taken up by dopaminergic neurons via DAT
- Accumulates in mitochondria
- Inhibits complex I
- Blocks electron transport
- ATP depletion
- ROS generation
- Substantia nigra pars compacta loss
- Ventral tegmental area spared
- Striatal terminal degeneration
- Specific neuron populations
- Dopamine depletion
- TH-positive neuron loss
- α-Synuclein phosphorylation
- Protein aggregation
- Single high-dose MPTP
- Rapid degeneration
- Used for mechanism studies
- Low-dose repeated exposure
- Progressive loss
- Models prodromal PD
- Multiple moderate doses
- Partial recovery possible
- Useful for intervention
- Most sensitive model
- Full PD-like syndrome
- Lewy bodies form
- Motor and non-motor features
- Good model system
- Motor symptoms
- Limited non-motor features
- Quick recovery potential
- Cats, dogs, monkeys
- Variable sensitivity
- Research use varies
- DAT imaging changes
- CSF biomarker shifts
- Metabolic alterations
- Dopamine depletion
- Neuronal loss markers
- Inflammation markers
- MAO-B inhibitors
- Complex I enhancers
- Antioxidants
- Anti-apoptotic compounds
- Cell transplantation
- Gene therapy
- Growth factors
- Exercise
The study of Mptp Induced Dopaminergic Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Langston et al., MPTP and Parkinson's disease (1983)
- Przedborski et al., MPTP mechanism of action (1995)
- Sundström et al., MPTP models in different species (1990)
- Bove & Perier, Neuroprotective strategies in MPTP model (2012)